A Phase 2 interventional study of Sotatercept in Anemia, Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, sponsored by Merck Sharp & Dohme LLC. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.
Among the 464 studies in Anemia with a site in United States, this one is the 196th largest by enrollment of the 395 interventional ones that give a count, is one of 25 that started in 2012, is one of 109 in phase 2, and was the 222nd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
464 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 136 · Phase 3 122 · Phase 4 34
First in 1992; this study’s year is marked. 25 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 395 interventional studies, 116 across the 50 observational. Of the 367 that completed or were terminated, 196 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 464 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 7 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
Add all 10 to your calendar (.ics) → With an account.
Among the 464 studies in Anemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sotatercept 0.1 mg/kg
Drug: Sotatercept
Sotatercept 0.3 mg/kg
Drug: Sotatercept
Sotatercept 0.5 mg/kg
Drug: Sotatercept
Sotatercept 1.0 mg/kg
Drug: Sotatercept
Sotatercept 1.5 mg/kg
Drug: Sotatercept
Sotatercept 2.0 mg/kg
Drug: Sotatercept
Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
Also known as: ACE-011, ActRIIA-IgG1Fc
Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate)
The responder rate includes non-transfusion dependent efficacy (NTDE) participants and transfusion dependent efficacy (TDE) participants. For non-transfusion dependence efficacy (NTDE) participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For transfusion dependence efficacy (TDE) participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.
Time frame: Day 2 to Day 142
Time to Erythroid Hematological Improvement (HI-E) Response
Time to first response = start date of first response (HI-E) - first dose date + 1 day. For NTDE participants (who required \< 4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For TDE participants (who required \>=4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.
Time frame: Day 1 to Day 87
Duration of Erythroid Hematological Improvement (HI-E)
The duration of HI-E response for participants who responded was (the last date of the consecutive hemoglobin \[Hgb\] measurements of the first \>=56 day interval) - (the first date of the consecutive Hgb measurements of the first \>=56 day interval) + 1 day.
Time frame: Day 1 to 183.7 weeks
Time to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression
Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in Hgb concentration by \>=2 g/dL - Transfusion dependence This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Disclosed are time to progression values only for participants who did progress to AML.
Time frame: Day 1 to 183.7 weeks
Time to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression
Progression to events of higher risk MDS used criteria from the International Prognostic Scoring System for MDS (IPSS) which assigns a prognostic score (0=good and increasing in risk by half-grades with the top score outlined below) for three prognostic variables: - Marrow blasts (score 0-2.0) - Karyotype (score 0-1.0) - Cytopenias: neutrophil, platelets, and Hg counts (score 0-0.5) The three individual scores are summed resulting in a full range of 0- 3.5 and placed into risk categories 0 = low risk 0.5-1.0 = intermediate-1 risk 1.5-2.0 = intermediate-2 risk \>=2.5 = high risk This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Data reported represent event times (weeks) for participants who did progress to higher risk MDS categories.
Time frame: Day 1 to 257.3 weeks
Kaplan-Meier Estimates for Progression-free Survival
Participants who had disease progression were considered to have events. Participants who died without acute myeloid leukemia (AML) were also considered to have events with the event date as the date of death. Those who did not have disease progression and who were lost to follow-up were censored at the last known disease progression assessment date. Participants without disease progression at the last follow-up contact were censored at the date of the last follow-up contact date. Disease Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in hemoglobin (Hgb) concentration by \>=2 g/dL - Transfusion dependence
Time frame: Day 1 to 257.3 weeks
Kaplan-Meier Estimates for Overall Survival (OS)
OS was defined as the time between start of treatment and the death/censored date. Participants who died (regardless of the cause of death) were considered to have an event. Participants who were alive at the end of the study, and participants who were lost to follow-up, were censored at the last date when subjects were known to be alive.
Time frame: Day 1 to 257.3 weeks
Pharmacokinetic Parameters of Sotatercept: Serum Concentration at Various Study Timepoints
Maximum observed serum concentration, obtained directly from the observed concentration versus time data.
Time frame: Cycle 1 Day 8 and !5 up to Cycle 2 Day 1
Participants With Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first treatment of the study medication and within 42 days after the last dose. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to the study drug and reported as 'Suspected' on the CRF. AEs with a missing relationship were treated as 'treatment-related' in data summaries.
Time frame: Day 1 up to 59.2 months
Dose Limiting Toxicities (DLTs)
The following were DLTs if the investigator suspected they were treatment related: 1. Increase to \>= 140 mmHg systolic blood pressure 2. Increase to \>=90 mmHg diastolic blood pressure 3. Increase to \>=140 systolic and increase \> 20 mmHg compared to baseline systolic 4. Increase to \>=90 mmHg diastolic and increase \> 20 mmHg compared to baseline diastolic 5. Introduction of new anti-hypertension medication during treatment 6. Increase in dose of baseline anti-hypertension medication during treatment 7. \>= Grade 2 (moderate severity or worse) hypertension as an adverse event
Time frame: Day 1 to 59.2 months
Number of Participants Who Achieved Red Blood Cell (RBC)-Transfusion Independence During the Erythroid Hematological Improvement (HI-E) Interval
Number of participants who achieved RBC-independence was defined as participants who required no RBC-transfusions during a 56-day interval of erythroid hematological improvement (HI-E). NTDE = non-transfusion dependence efficacy participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy TDE = transfusion dependence efficacy participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy
Time frame: Day 2 to Day 142
Participants were stratified by concentration of serum erythropoietin (EPO) (\<500 versus ≥500 IU/L), by number of transfusions within 56 days of study enrollment (\<4 versus ≥4 units of red blood cells) and assigned randomly to 0.1 mg/kg and 0.3 mg/kg arms.
| Milestone | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| Started | 7 | 6 | 21 | 35 | 5 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 6 | 21 | 35 | 5 |
| Withdrew: Disease relapse | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 | 2 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 1 | 1 |
| Withdrew: Lack of therapeutic effect | 7 | 4 | 13 | 20 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 9 | 1 |
The responder rate includes non-transfusion dependent efficacy (NTDE) participants and transfusion dependent efficacy (TDE) participants. For non-transfusion dependence efficacy (NTDE) participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For transfusion dependence efficacy (TDE) participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.
| percentage of participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| All participants | 0 | 66.7 | 42.9 | 60.0 | 40.0 |
| NTDE subpopulation | — | — | 33.3 | 62.5 | 100 |
| TDE subpopulation | 0 | 66.7 | 44.4 | 59.3 | 25.0 |
Time to first response = start date of first response (HI-E) - first dose date + 1 day. For NTDE participants (who required \< 4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For TDE participants (who required \>=4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.
| days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| All participants | — | 24.0 (2 to 44) | 1.0 (1 to 2) | 1.0 (1 to 86) | 48 (9 to 87) |
| NTDE subpopulation | — | — | 1.0 (1 to 1) | 1.0 (1 to 52) | 9.0 (9 to 9) |
| TDE subpopulation | — | 24.0 (2 to 44) | 1.5 (1 to 2) | 1.5 (1 to 86) | 87 (87 to 87) |
The duration of HI-E response for participants who responded was (the last date of the consecutive hemoglobin \[Hgb\] measurements of the first \>=56 day interval) - (the first date of the consecutive Hgb measurements of the first \>=56 day interval) + 1 day.
| days | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| All participants | — | 62.5 (62 to 69) | 104.0 (56 to 1794) | 133.0 (58 to 1554) | 96.0 (58 to 134) |
| NTDE subpopulation | — | — | 79.0 (79 to 79) | 1043.0 (69 to 1554) | 134.0 (134 to 134) |
| TDE subpopulation | — | 62.5 (62 to 69) | 105.5 (56 to 1794) | 96.5 (58 to 1033) | 58.0 (58 to 58) |
Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in Hgb concentration by \>=2 g/dL - Transfusion dependence This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Disclosed are time to progression values only for participants who did progress to AML.
| weeks | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| Time to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression | — | — | 45.6 | 78.0 | — |
Progression to events of higher risk MDS used criteria from the International Prognostic Scoring System for MDS (IPSS) which assigns a prognostic score (0=good and increasing in risk by half-grades with the top score outlined below) for three prognostic variables: - Marrow blasts (score 0-2.0) - Karyotype (score 0-1.0) - Cytopenias: neutrophil, platelets, and Hg counts (score 0-0.5) The three individual scores are summed resulting in a full range of 0- 3.5 and placed into risk categories 0 = low risk 0.5-1.0 = intermediate-1 risk 1.5-2.0 = intermediate-2 risk \>=2.5 = high risk This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Data reported represent event times (weeks) for participants who did progress to higher risk MDS categories.
| weeks | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| Time to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression | 15.1 | — | 24.7 | 67.4 | — |
Participants who had disease progression were considered to have events. Participants who died without acute myeloid leukemia (AML) were also considered to have events with the event date as the date of death. Those who did not have disease progression and who were lost to follow-up were censored at the last known disease progression assessment date. Participants without disease progression at the last follow-up contact were censored at the date of the last follow-up contact date. Disease Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in hemoglobin (Hgb) concentration by \>=2 g/dL - Transfusion dependence
| weeks | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| Kaplan-Meier Estimates for Progression-free Survival | 82.7 (15.1 to 82.7) | NA (91.1 to NA) | NA (58.6 to NA) | NA (NA to NA) | NA (79.9 to NA) |
OS was defined as the time between start of treatment and the death/censored date. Participants who died (regardless of the cause of death) were considered to have an event. Participants who were alive at the end of the study, and participants who were lost to follow-up, were censored at the last date when subjects were known to be alive.
| weeks | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| Kaplan-Meier Estimates for Overall Survival (OS) | 82.7 (NA to NA) | NA (91.00 to NA) | NA (58.6 to NA) | NA (NA to NA) | NA (79.1 to NA) |
Maximum observed serum concentration, obtained directly from the observed concentration versus time data.
| ng/mL | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 288.06 ± 70.94 | 1426.00 ± 27.76 | 2237.46 ± 40.77 | 6525.37 ± 28.31 | 12886.14 ± 30.47 |
| Cycle 1 Day 15 | 240.31 ± 75.32 | 1207.68 ± 16.14 | 1869.52 ± 36.97 | 5149.74 ± 36.04 | 8303.73 ± 43.57 |
| Cycle 2 Day 1 | 252.20 ± 28.43 | 957.58 ± 18.63 | 1323.91 ± 44.40 | 3467.58 ± 57.06 | 5329.63 ± 38.27 |
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first treatment of the study medication and within 42 days after the last dose. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to the study drug and reported as 'Suspected' on the CRF. AEs with a missing relationship were treated as 'treatment-related' in data summaries.
| Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| >= 1 Treatment-emergent adverse event (TEAE) | 6 | 4 | 20 | 34 | 5 |
| >=1 Treatment-related TEAE | 2 | 3 | 7 | 18 | 4 |
| >=1 Serious TEAE | 1 | 2 | 6 | 10 | 2 |
| >=1 Serious TEAE related to treatment | 0 | 0 | 0 | 0 | 1 |
| >=1 TEAE severity 3 or 4 | 1 | 2 | 9 | 13 | 2 |
| >=1 TEAE severity grade 3/4 related to treatment | 0 | 0 | 1 | 0 | 1 |
| >=1 TEAE leading to death | 0 | 1 | 0 | 0 | 0 |
| >=1 TEAE leading to dose reduction | 0 | 0 | 0 | 0 | 0 |
| >=1 TEAE leading to dose interruption | 0 | 1 | 2 | 9 | 1 |
| >=1 TEAE leading to dose interruption + reduction | 0 | 0 | 0 | 1 | 0 |
| >= 1 TEAE leading to drug discontinuation | 0 | 2 | 2 | 3 | 2 |
The following were DLTs if the investigator suspected they were treatment related: 1. Increase to \>= 140 mmHg systolic blood pressure 2. Increase to \>=90 mmHg diastolic blood pressure 3. Increase to \>=140 systolic and increase \> 20 mmHg compared to baseline systolic 4. Increase to \>=90 mmHg diastolic and increase \> 20 mmHg compared to baseline diastolic 5. Introduction of new anti-hypertension medication during treatment 6. Increase in dose of baseline anti-hypertension medication during treatment 7. \>= Grade 2 (moderate severity or worse) hypertension as an adverse event
| Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| 1. Increase to >= 140 mmHg systolic | 1 | 1 | 8 | 19 | 2 |
| 2. Increase to >=90 mmHg diastolic | 0 | 0 | 2 | 2 | 1 |
| 3. =140 systolic and increase > 20 mmHg base | 0 | 1 | 5 | 10 | 2 |
| 4. >=90 mmHg diastolic and increase > 20 mmHg base | 0 | 0 | 2 | 2 | 1 |
| 5. Introduction of new anti-hypertension med | 0 | 0 | 4 | 3 | 1 |
| 6. Incre in dose of baseline anti-hypertension med | 0 | 0 | 0 | 0 | 0 |
| 7.>= Grade 2 hypertension TEAE | 0 | 1 | 2 | 4 | 1 |
Number of participants who achieved RBC-independence was defined as participants who required no RBC-transfusions during a 56-day interval of erythroid hematological improvement (HI-E). NTDE = non-transfusion dependence efficacy participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy TDE = transfusion dependence efficacy participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy
| Participants | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| All participants | 0 | 1 | 3 | 15 | 1 |
| NTDE subpopulation | — | — | 1 | 6 | 1 |
| TDE subpopulation | 0 | 1 | 2 | 9 | 0 |
Collected over Day 1 up to 60.7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotatercept 0.1 mg/kg | 1/7 (14.3%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Sotatercept 0.3 mg/kg | 1/6 (16.7%) | 2/6 (33.3%) | 4/6 (66.7%) |
| Sotatercept 0.5 mg/kg | 6/21 (28.6%) | 6/21 (28.6%) | 18/21 (85.7%) |
| Sotatercept 1.0 mg/kg | 6/35 (17.1%) | 10/35 (28.6%) | 32/35 (91.4%) |
| Sotatercept 2.0 mg/kg | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Event | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/7 | 0/6 | 1/21 | 0/35 | 1/5 |
| Transfusion reactionInjury, poisoning and procedural complications | 0/7 | 0/6 | 0/21 | 0/35 | 1/5 |
| Blood pressure increasedInvestigations | 0/7 | 0/6 | 0/21 | 0/35 | 1/5 |
| PneumoniaInfections and infestations | 0/7 | 1/6 | 1/21 | 0/35 | 0/5 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/7 | 1/6 | 0/21 | 0/35 | 0/5 |
| Aortic stenosisVascular disorders | 0/7 | 1/6 | 0/21 | 0/35 | 0/5 |
| BronchitisInfections and infestations | 1/7 | 0/6 | 0/21 | 0/35 | 0/5 |
| InfluenzaInfections and infestations | 1/7 | 0/6 | 0/21 | 0/35 | 0/5 |
| Hip fractureInjury, poisoning and procedural complications | 0/7 | 0/6 | 2/21 | 0/35 | 0/5 |
| ColitisGastrointestinal disorders | 0/7 | 0/6 | 0/21 | 3/35 | 0/5 |
| Event | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/7 | 1/6 | 4/21 | 5/35 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 2/6 | 7/21 | 9/35 | 2/5 |
| NauseaGastrointestinal disorders | 0/7 | 1/6 | 4/21 | 8/35 | 2/5 |
| Urinary tract infectionInfections and infestations | 1/7 | 0/6 | 0/21 | 4/35 | 2/5 |
| DizzinessNervous system disorders | 1/7 | 2/6 | 1/21 | 6/35 | 2/5 |
| Oedema peripheralGeneral disorders | 2/7 | 2/6 | 6/21 | 11/35 | 0/5 |
| FallInjury, poisoning and procedural complications | 0/7 | 2/6 | 1/21 | 1/35 | 0/5 |
| FatigueGeneral disorders | 0/7 | 1/6 | 6/21 | 11/35 | 1/5 |
| ConstipationGastrointestinal disorders | 0/7 | 1/6 | 6/21 | 3/35 | 0/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/7 | 1/6 | 6/21 | 2/35 | 1/5 |
All randomized participants
| Age, Continuous(years) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| Mean | 67 ± 8.3 | 75 ± 6.9 | 69 ± 8.0 | 71 ± 8.2 | 69 ± 13.0 | 70 ± 8.4 |
| Age, Customized(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| <65 years | 3 | 0 | 7 | 6 | 1 | 17 |
| >=65 - <75 years | 2 | 3 | 8 | 17 | 2 | 32 |
| >=75 years | 2 | 3 | 6 | 12 | 2 | 25 |
| Sex: Female, Male(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 0 | 4 | 17 | 4 | 28 |
| Male | 4 | 6 | 17 | 18 | 1 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 7 | 6 | 13 | 19 | 4 | 49 |
| Unknown or Not Reported | 0 | 0 | 6 | 16 | 1 | 23 |
| Race (NIH/OMB)(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 7 | 6 | 14 | 18 | 3 | 48 |
| More than one race | NA | NA | NA | NA | NA | NA |
| Unknown or Not Reported | 0 | 0 | 7 | 16 | 1 | 24 |
| Region of Enrollment(Participants) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| United States | 7 | 6 | 15 | 18 | 4 | 50 |
| France | 0 | 0 | 6 | 17 | 1 | 24 |
| Height(meters) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| Mean | 1.70 ± 0.110 | 1.75 ± 0.054 | 1.70 ± 0.093 | 1.68 ± 0.089 | 1.56 ± 0.043 | 1.68 ± 0.095 |
| Weight(kg) | Sotatercept 0.1 mg/kg | Sotatercept 0.3 mg/kg | Sotatercept 0.5 mg/kg | Sotatercept 1.0 mg/kg | Sotatercept 2.0 mg/kg | Total |
|---|---|---|---|---|---|---|
| Mean | 85.3 ± 21.79 | 79.5 ± 13.90 | 77.9 ± 13.97 | 73.5 ± 15.55 | 56.4 ± 7.25 | 75.2 ± 16.14 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2012 to primary completion in Apr 2018, 65 months.
Results were first posted in Jun 2019, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 65 months is above that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept